ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2019

Oct 12, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2019-10-10

Reporting Person: Anzalone Christopher Richard (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-10-10	Common Stock	M	56325	$5.20	Acquired	2178228	Direct
2019-10-10	Common Stock	S	56325	$31.83	Disposed	2121903	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-10-10	Stock Option (right to buy)	$5.20	M	56325	Disposed	2020-03-04	Common Stock (56325)	Direct

Footnotes

F1: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $32.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2: Includes a total of 933,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole.

F3: Represents first vesting date. Option vested over two years from date of grant.